SARCLISA — SANOFI AVENTIS US, approved 2026-06-26 (BLA761113).
3,806 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.